News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Phase 2 Clinical Data On Tokai Pharmaceuticals’ Galeterone In Advanced Prostate Cancer To Be Presented At 2014 American Society of Clinical Oncology GU Symposium


1/9/2014 7:23:47 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers, today announced that new data from the ARMOR2 Phase 2 study of its lead drug candidate, galeterone (TOK-001), in patients with castration-resistant prostate cancer (CRPC) will be presented at the 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES